Fennec Pharma

50 articles with Fennec Pharma

• Fennec Pharmaceuticals Announces Updated NCCN Clinical Practice Guidelines Recommend PEDMARK® (sodium thiosulfate injection) to Reduce the Risk of Cisplatin-Induced Hearing Loss in Pediatric Patients

  1/25/2023

  Fennec Pharmaceuticals Inc. today announced that the National Comprehensive Cancer Network® (NCCN) has updated its clinical practice guidelines for Adolescent and Young Adult (AYA) Oncology to include PEDMARK® (sodium thiosulfate injection) to help reduce the risk of ototoxicity (hearing loss) associated with cisplatin use in pediatric patients with localized, non-metastatic solid tumors.

• Fennec Pharmaceuticals Announces Third Quarter 2022 Financial Results and Provides Business Update

  11/11/2022

  Fennec Pharmaceuticals Inc. today reported its financial results for the fiscal quarter ended September 30, 2022 and provided a business update.

• Berkshire Sterile client receives FDA approval on product indicated to reduce risk of hearing loss for childhood cancer patients

  9/29/2022

  Berkshire Sterile Manufacturing’s client, Fennec Pharmaceuticals Inc., received FDA approval of their drug product, PEDMARK – a sodium thiosulfate Injection with an indication to reduce the risk of ototoxicity associated with cisplatin in pediatric patients one month of age and older with localized, non-metastatic solid tumors.

• 

  Money on the Move: Eagle, Elucidata, Prime Medicine and More

  9/28/2022

  ​​​​​​​Funding initiatives this week saw money flow into cancer, rare liver diseases, respiratory depression, chemotherapy-related toxicities and a cutting-edge machine learning platform.

• Fennec Pharmaceuticals Announces Second Closing of $20 Million Investment from Petrichor

  9/26/2022

  Fennec Pharmaceuticals Inc. today announced that it has completed the second closing of $20 million of senior secured promissory notes under our previously announced investment agreement with Petrichor Healthcare Capital Management.

• 

  FDA Action Alert: Regeneron, Spectrum and More

  9/19/2022

  The FDA has two PDUFA dates on its calendar this week, with two extra days slotted for an advisory committee meeting to evaluate drug applications from three companies.

• Fennec Pharmaceuticals Closes First $5 Million Investment From Petrichor

  8/22/2022

  Fennec Pharmaceuticals Inc. today announced it has completed the first closing of US$5 million of senior secured promissory notes under our previously announced investment agreement with Petrichor Healthcare Capital Management.

• Fennec Pharmaceuticals Announces Up to $45 Million Investment From Petrichor

  8/1/2022

  Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced up to a US$45 million investment from Petrichor Healthcare Capital Management ("Petrichor").

• Fennec Announces Results of Annual Meeting - June 14, 2022

  6/14/2022

  Fennec Pharmaceuticals Inc. announced that the nominees listed in the management proxy circular dated April 20, 2022 for the Annual General Meeting of Shareholders were elected as directors of the Company at the Annual General Meeting of Shareholders held in New York, New York on June 14, 2022.

• Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences - May 23, 2022

  5/23/2022

  Fennec Pharmaceuticals Inc., a specialty pharmaceutical company focused on the development of PEDMARKTM for the prevention of platinum-induced ototoxicity in pediatric patients, announced that the Company will be participating in upcoming conferences.

• Fennec Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Business Update

  5/12/2022

  Fennec Pharmaceuticals Inc. reported its financial results for the fiscal quarter ended March 31, 2022 and provided a business update.

• Fennec Pharmaceuticals Announces FDA Acceptance for Filing of New Drug Application Resubmission for PEDMARK™

  4/27/2022

  Fennec Pharmaceuticals Inc., a specialty pharmaceutical company, announced that the U.S. Food and Drug Administration has accepted for filing the Company’s resubmitted New Drug Application for PEDMARKᵀᴹ for the prevention of platinum-induced ototoxicity in pediatric patients one month to <18 years of age with localized, non-metastatic, solid tumors.

• Fennec Pharmaceuticals to Participate in the 2022 Maxim Virtual Growth Conference

  3/25/2022

  Fennec Pharmaceuticals Inc. announced that the Company will be participating in the 2022 Maxim Group Virtual Growth Conference, taking place March 28-30, 2022.

• Fennec Pharmaceuticals Announces Fiscal Year 2021 Financial Results And Provides Business Update

  2/28/2022

  Fennec Pharmaceuticals Inc. reported its financial results for the fiscal year ended December 31, 2021 and provided a business update.

• Fennec Pharmaceuticals Announces Management Change - Jan 31, 2022

  1/31/2022

  Fennec Pharmaceuticals Inc. announced that Shubh Goel, the Company’s chief commercial officer, has tendered her resignation and will depart Fennec in late February.

• Fennec Pharmaceuticals Expects to Receive Complete Response Letter from the FDA for its New Drug Application for PEDMARK™ to Prevent Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, Non-Metastatic, Solid Tumors

  11/29/2021

  Fennec Pharmaceuticals Inc. announced that it expects to receive a Complete Response Letter after the PDUFA target action date of November 27, 2021 from the U.S. FDA regarding its New Drug Application for PEDMARKTM, for intravenous administration for the prevention of ototoxicity associated with cisplatin chemotherapy in pediatric patients ≥1 month to 18 years of age with localized, non-metastatic, solid tumors.

• Fennec Pharmaceuticals Announces Third Quarter 2021 Financial Results and Provides Business Update

  11/10/2021

  Fennec Pharmaceuticals Inc., a specialty pharmaceutical company focused on the development of PEDMARK™ for the prevention of platinum-induced ototoxicity in pediatric patients, reported its financial results for the third quarter ended September 30, 2021 and provided a business update.

• Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences - Sep 09, 2021

  9/9/2021

  Fennec Pharmaceuticals Inc. announced that management will participate in three upcoming virtual investor conferences, including H.C. Wainwright 23rd Annual Global Investment Conference taking place September 13-15, 2021, the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit taking place September 20-23, 2021, and the 2021 Cantor Virtual Global Healthcare Conference taking place September 27-30, 2021.

• Fennec Pharmaceuticals Announces Second Quarter 2021 Financial Results and Provides Business Update

  8/10/2021

  Fennec Pharmaceuticals Inc., a specialty pharmaceutical company focused on the development of PEDMARK™ for the prevention of platinum-induced ototoxicity in pediatric patients, reported its financial results for the second quarter ended June 30, 2021 and provided a business update.

• Fennec Announces Results of Annual Meeting - June 29, 2021

  6/29/2021

  Fennec Pharmaceuticals Inc. announced that the nominees listed in the management proxy circular dated May 14, 2021 for the Annual General Meeting of Shareholders were elected as directors of the Company at the Annual General Meeting of Shareholders held in Irvine, California and online on June 29, 2021.